Humanization and simultaneous optimization of monoclonal antibody

Methods in Molecular Biology

Volumn 1060, Issue , 2014, Pages 123-137

  Kuramochi, T ^a   Igawa, T ^a   Tsunoda, H ^a   Hattori, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Humanization; Immunogenicity; Optimization; Pharmacokinetics; Protein expression; Stability

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGENIC VARIATION; ARTICLE; BINDING AFFINITY; BIOTECHNOLOGY; DIFFERENTIAL SCANNING CALORIMETRY; HOST CELL; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ANTIBODY HUMANIZATION; HUMAN; MOLECULE; NONHUMAN; PROTEIN STABILITY;

ANIMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; HUMANS; PROTEIN ENGINEERING;

EID: 84931262849     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-586-6_7     Document Type: Article

References (43)

1. Nishimoto N, Kishimoto T (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 181:151-1
2. Buch MH, Emery P (2011) New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 23:245-2
3. Tanaka T, Kishimoto T (2012) Immunotherapeutic implication of IL-6 blockade. Immunotherapy 4:87-1
4. Breedveld F (2011) The value of early intervention in RA-a window of opportunity. Clin Rheumatol 33:33-3
5. Pangalis GA et al (2001) Campath-1H (anti- CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 18:99-1
6. Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115-1
7. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278-2
8. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76-9
9. Schroff RW et al (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879-885
10. Shawler DL et al (1985) Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135:1530-1535
11. Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312: 643-646
12. Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10
13. Jones PT et al (1986) Replacing the complementarity- determining regions in a human antibody with those from a mouse. Nature 321:522-525
14. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619-1633
15. Wu H, Dall'Acqua WF (2005) Humanized antibodies and their applications. Methods 36:1-2
16. Tan P et al (2002) "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol 169:1119-1125
17. Hwang WY et al (2005) Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 36:35-42
18. Pelat T et al (2008) Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 384:1400-1407
19. Tamura M et al (2000) Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol 164:1432-1441
20. Gonzales NR et al (2004) SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol Immunol 1:863-872
21. Kashmiri SV et al (2005) SDR grafting-a new approach to antibody humanization. Methods 36:25-34
22. Maloney DG (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366:2008-2016
23. Ducancel F, Muller BH (2012) Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs 4:445-457
24. Igawa T et al (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3:243-252
25. Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:685-691
26. Greer J (1991) Comparative modeling of homologous proteins. Methods Enzymol 202:239-252
27. Morea V, Lesk AM, Tramontano A (2000) Antibody modeling: implications for engineering and design. Methods 20:267-279
28. Whitelegg NR, Rees AR (2000) WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng Des Sel 13:819-824
29. Marcatili P, Rosi A, Tramontano A (2008) PIGS: automatic prediction of antibody structures. Bioinformatics 24:1953-1954
30. Sircar A, Kim ET, Gray JJ (2009) RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res 37:474-479
31. Almagro JC et al (2011) Antibody modeling assessment. Proteins 79:3050-3066
32. Ewert S, Honegger A, Plückthun A (2004) Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structurebased framework engineering. Methods 34:184-199
33. Ewert S et al (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325:531-553
34. Honegger A, Plückthun A (2001) The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J Mol Biol 309:687-699
35. Jung S et al (2001) The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains. J Mol Biol 9:701-716
36. Honegger A et al (2009) The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng Des Sel 22:121-134
37. Igawa T et al (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385-392
38. Glanville J et al (2009) Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 106:20216-20221
39. Van WI et al (2007) Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7:405-418
40. Perry LC, Jones TD, Baker MP (2008) New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R&D 9:385-396
41. Bryson CJ, Jones TD, Baker MP (2010) Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24:1-8
42. Koren E et al (2007) Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:26-32
43. De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620-626